Multidrug resistance proteins and folate supplementation: Therapeutic implications for antifolates and other classes of drugs in cancer treatment

Cancer Chemotherapy and Pharmacology

Volumn 58, Issue 1, 2006, Pages 1-12

  Hooijberg, J H ^a,c   De Vries, N A ^a   Kaspers, G J L ^a   Pieters, R ^b   Jansen, G ^a   Peters, G J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^c Location Alkmaar   (Netherlands)

Author keywords

ABC transporters; Antifolates; Breast cancer resistance protein; Folate homeostasis; Folates; Multidrug resistance proteins; Multiple drug resistance

Indexed keywords

ADEFOVIR; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BGC 9331; BREAST CANCER RESISTANCE PROTEIN; CAMPTOTHECIN DERIVATIVE; CISPLATIN; DOCETAXEL; EKI 785; ETOPOSIDE; FLUOROURACIL; FOLIC ACID; FOLIC ACID ANTAGONIST; FOLINIC ACID; GEFITINIB; GW 1843; IMATINIB; METHOTREXATE; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3; MULTIDRUG RESISTANCE PROTEIN 4; MULTIDRUG RESISTANCE PROTEIN 5; MULTIDRUG RESISTANCE PROTEIN 6; MULTIDRUG RESISTANCE PROTEIN 7; MULTIDRUG RESISTANCE PROTEIN 8; MULTIDRUG RESISTANCE PROTEIN 9; NOLATREXED; OSI 7904; PEMETREXED; PLEVITREXED; RALTITREXED; TIOGUANINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VINCA ALKALOID; ZIDOVUDINE;

ANTINEOPLASTIC ACTIVITY; CANCER THERAPY; CELL MEMBRANE; DRUG EFFICACY; DRUG SENSITIVITY; HOMEOSTASIS; HUMAN; LEUKEMIA; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SOLID TUMOR; VITAMIN SUPPLEMENTATION;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; FOLIC ACID; FOLIC ACID ANTAGONISTS; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; P-GLYCOPROTEINS;

EID: 33645976121     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-005-0141-1     Document Type: Review

References (149)

1. Danø K (1973) Active outward transport of daunomycin in resistant Ehrlich ascites. Biochim Biophys Acta 323:466-483
2. Borst P, Elferink RO (2002) Mammalian ABC transporters in health and disease. Annu Rev Biochem 71:537-592
3. Kruh GD, Belinsky MG (2003) The MRP family of drug efflux pumps. Oncogene 22:7537-7552
4. Scotto KW (2003) Transcriptional regulation of ABC drug transporters. Oncogene 22:7496-7511
5. Haimeur A, Conseil G, Deeley RG, Cole SP (2004) The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. Curr Drug Metab 5:21-53
6. Cole SP, Bhardwaj G, Gerlach J, Mackie JE, Grant C, Almquist KC, Stewart AJ, Kurz E, Duncan AM, Deeley RG (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258:1650-1654
7. Dean M, Allikmets R (2001) Complete characterization of the human ABC gene family. J Bioenerg Biomembr 33:475-479
8. Borst P, Evers R, Kool M, Wijnholds J (1999) The multidrug resistance protein family. Biochim Biophys Acta 146:347-357
9. Borst P, Evers R, Kool M, Wijnholds J (2000) A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 92:1295-1302
10. Leslie EM, Deeley RG, Cole SP (2001) Toxicological relevance of the multidrug resistance protein 1, MRP1 (ABCC1) and related transporters. Toxicology 167:3-23
11. Bodo A, Bakos E, Szeri F, Varadi A, Sarkadi B (2003) The role of multidrug transporters in drug availability, metabolism and toxicity. Toxicol Lett 140:133-143
12. Yabuuchi H, Shimizu H, Takayanagi S et al (2001) Multiple splicing variants of two new human ATP-binding cassette transporters, ABCC11 and ABCC12. Biochem Biophys Res Commun 288:933-939
13. Broxterman HJ, Giaccone G, Lankelma J (1995) Multidrug resistance proteins and other drug transport-related resistance to natural product agents. Curr Opin Oncol 7:532-540
14. Jedlitschky G, Leier I, Buchholz U, Center M, Keppler D (1994) ATP-dependent transport of glutathione S-conjugates by the multidrug resistance-associated protein. Cancer Res 54:4833-4836
15. Leier I, Jedlitschky G, Buchholz U, Center M, Cole SP, Deeley RG, Keppler D (1996) ATP-dependent glutathione disulphide transport mediated by the MRP gene-encoded conjugate export pump. Biochem J 314:433-437
16. Müller M, Meijer C, Zaman GJ, Borst P, Scheper RJ, Mulder NH, de Vries EG, Jansen PL (1994) Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc Natl Acad Sci USA 91:13033-13037
17. Ishikawa T, Akimaru K, Kuo MT, Priebe W, Suzuki M (1995) How does the MRP/GS-X pump export doxorubicin? J Natl Cancer Inst 87:1639-1640
18. König J, Nies AT, Cui Y, Leier I, Keppler D (1999) Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2 mediated drug resistance. Biochem Biophys Acta 1461:377-394
19. Hirohashi T, Suzuki H, Sugiyama Y (1999) Characterization of the transport properties of cloned rat multidrug resistance-associated protein 3 (MRP3). J Biol Chem 274:15181-15185
20. Schuetz JD, Connelly MC, Sun D et al (1999) MRP4: a previously unidentified factor in resistance to nucleotide-based antiviral drugs. Nat Med 5:1048-1051
21. Reid G, Wielinga P, Zelcer N, van der Heijden I, Kuil A, de Haas M, Wijnholds J, Borst P (2003) The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal anti-inflammatory drugs. Proc Natl Acad Sci USA 100:9244-9249
22. Wijnholds J, Mol CA, van Deemter L, de Haas M, Scheffer GL, Baas F, Beijnen JH, Scheper RJ, Hatse S, De Clercq E, Balzarini J, Borst P (2000) Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc Natl Acad Sci USA 97:7476-7481
23. McAleer MA, Breen MA, White NL, Matthews N (1999) pABC11 (also known as MOAT-C and MRP5), a member of the ABC family of proteins, has anion transporter activity but does not confer multidrug resistance when overexpressed in human embryonic kidney 293 cells. J Biol Chem 274:23541-23548
24. Wielinga P, Hooijberg JH, Gunnarsdottir S, Kathmann I, Reid G, Zelcer N, Van der Born K, De Haas M, Van der Heiden I, Kaspers GJ, Wijnholds J, Jansen G, Peters GJ, Borst P (2005) The human multidrug resistance protein MRP5 transports folates and can mediate cellular resistance against antifolates. Cancer Res 65:4425-4430
25. Belinsky MG, Chen ZS, Shchaveleva I, Zeng H, Kruh GD (2002) Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6). Cancer Res 62:6172-6177
26. Hopper-Borge E, Chen ZS, Shchaveleva I, Belinsky MG, Kruh GD (2004) Analysis of the drug resistance profile of multidrug resistance protein 7 (ABCC10): resistance to docetaxel. Cancer Res 64:4927-4930
27. Guo Y, Kotova E, Chen ZS, Lee K, Hopper-Borge E, Belinsky MG, Kruh GD (2003) MRP8, ATP-binding cassette 11 (ABCC11), is a cyclic nucleotide efflux pump and a resistance factor for fluoropyrimidines 2′,3′-dideoxycytidine and 9′-(2′-phosphonylmethoxyethyl)adenine. J Biol Chem 278:29509-29514
28. Chen ZS, Guo Y, Belinsky MG, Kotova E, Kruh GD (2005) Transport of bile acids, sulfated steroids, estradiol 17-beta-D-glucuronide, and leukotriene C4 by human multidrug resistance protein 8 (ABCC11). Mol Pharmacol 67:545-557
29. Flens MJ, Zaman GJ, van der Valk P, Izquierdo MA, Schroeijers AB, Scheffer GL, van der Groep P, de Haas M, Meijer CJ, Scheper RJ (1996) Tissue distribution of the multidrug resistance protein. Am J Pathol 148:1237-1247
30. Kool M, de Haas M, Scheffer GL, Scheper RJ, van Eijk MJT, Juijn JA, Baas F, Borst P (1997) Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res 57:3537-3547
31. Kool M, Van der Linden M, de Haas M, Baas F, Borst P (1999) Expression of human MRP6, a homologue of the multidrug resistance protein gene MRP1, in tissues and cancer cells. Cancer Res 59:175-182
32. Scheffer GL, Kool M, Heijn M, de Haas M, Pijnenborg AC, Wijnholds J, van Helvoort A, de Jong MC, Hooijberg JH, Mol CA, van der Linden M, de Vree JM, van der Valk P, Elferink RP, Borst P, Scheper RJ (2000) Specific detection of multidrug resistance proteins MRP1, MRP2, MRP3, MRP5, and MDR3 P-glycoprotein with a panel of monoclonal antibodies. Cancer Res 60:5269-5277
33. Hipfner DR, Mao Q, Qiu W, Leslie EM, Gao M, Deeley RG, Cole SP (1999) Monoclonal antibodies that inhibit the transport function of the 190-kDa multidrug resistance protein, MRP. Localization of their epitopes to the nucleotide-binding domains of the protein. J Biol Chem 274:15420-15426
34. Nooter K, Westerman MA, Flens MJ, Zaman GJR, Scheper RJ, van Wingerden KE, Burger H, Oostrum R, Boersma T, Sonneveld P, Graterna JW, Kok T, Eggermont AMM, Bosman FT, Stoter G (1995) Expression of the multidrug resistance-associated protein (MRP) gene in human cancers. Clin Cancer Res 1:1301-1310
35. Giaccone G, van Ark-Otte J, Rubio GJ, Gazdar AF, Broxterman HJ, Dingemans AM, Flens MJ, Scheper RJ, Pinedo HM (1996) MRP is frequently expressed in human lung-cancer cell lines, in non-small-cell lung cancer and in normal lungs. Int J Cancer 66:760-767
36. Linn SC, Pinedo HM, van Ark-Otte J, van der Valk P, Hoekman K, Honkoop AH, Vermerken JB, Giaccone G (1997) Expression of drug resistance proteins in breast cancer, in relation to chemotherapy. Int J Cancer 71:787-795
37. Kubo H, Sumizawa T, Koga K, Nishiyama K, Takebayashi Y, Chuman Y, Furukawa T, Akiyama S, Ohi Y (1996) Expression of the multidrug resistance-associated protein (MRP) gene in urothelial carcinomas. Int J Cancer 69:488-494
38. Berger W, Elbling L, Hauptmann E, Micksche M (1997) Expression of the multidrug resistance associated protein (MRP) and chemoresistance of human non-small-cell lung cancer cells. Int J Cancer 73:84-93
39. Zervos PH, Allen RH, Thornton DE, Thiem PA (1997) Functional folate status as a prognostic indicator of toxicity in clinical trials of the multitargeted antifolate LY231514. Eur J Cancer (suppl)33, S18
40. Ohishi Y, Oda Y, Uchiumi T, Kobayashi H, Hirakawa T, Miyamoto S, Kinukawa N, Nakano H, Kuwano M, Tsuneyoshi M (2002) ATP binding cassette superfamily transporter gene expression in human primary ovarian carcinoma. Clin Cancer Res 8:3767-3775
41. Sauerbrey A, Voigt A, Wittig S, Hafer R, Zintl F (2002) Messenger RNA analysis of the multidrug resistance related protein (MRP1) and the lung resistance protein (LRP) in de novo and relapsed childhood acute lymphoblastic leukemia. Leuk Lymphoma 43:875-879
42. Van den Heuvel-Eibrink MM, Sonneveld P, Pieters R (2000) The prognostic significance of membrane transport-associated multidrug resistance (MDR) proteins in leukemia. Int J Clin Pharmacol Ther 38:94-110
43. Schneider E, Cowan KH, Bader H, Toomey S, Schwartz GN, Karp JE, Burke PJ, Kaufmann SH (1995) Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia. Blood 85:186-193
44. Ikeda K, Oka M, Yamada Y, Soda H, Fukuda M, Kinoshita A, Tsukamoto K, Noguchi Y, Isomoto H, Takeshima F, Murase K, Kamihira S, Tomonaga M, Kohno S (1999) Adult T-cell leukemia cells over-express the multidrug-resistance-protein (MRP) and lung resistance-protein (LRP) genes. Int J Cancer 82:599-604
45. Ogretmen B, Barredo JC, Safa AR (2000) Increased expression of lung resistance-related protein and multidrug resistance-associated protein messenger RNA in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 22:45-49
46. Ohno N, Tani A, Chen ZS, Uozumi K, Kanada S, Akiba S, Ren XQ, Furukawa T, Sumizawa T, Arima T, Akiyama SI (2001) Prognostic significance of multidrug resistance protein in adult T-cell leukemia. Clin Cancer Res 7:3120-3126
47. Steinbach D, Wittig S, Cario G, Viehmann S, Mueller A, Gruhn B, Haefer R, Zintl F, Sauerbrey A (2003) The multidrug resistance associated protein 3 (MRP3) is associated with a poor outcome in childhood ALL and may account for the worse prognosis in male patients and T-cell immunophenotype. Blood 102:4493-4498
48. Den Boer ML, Rieters R, Kazemier KM, Rottier MMA, Zwaan CM, Kaspers G-J-L, Janka-Schaub G, Henze G, Veerman AJP (1998) Relationship between major vault resistance protein, MRP, P-gp expression and drug resistance in childhood leukemia. Blood 91:2092-2098
49. Stam RW, van den Heuvel-Eibrink MM, den Boer ML, Ebus ME, Janka-Schaub GE, Allen JD, Pieters R (2004) Multidrug resistance genes in infant acute lymphoblastic leukemia: Ara-C is not a substrate for the breast cancer resistance protein. Leukemia 18:78-83
50. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD (1998) A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 95:15665-15670
51. Doyle LA, Ross DD (2003) Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22:7340-7358
52. Ross DD, Yang W, Abruzzo LV, Dalton WS, Schneider E, Lage H, Dietel M, Greenberger L, Cole SP, Doyle LA (1999) Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J Natl Cancer Inst 91:429-433
53. Xu J, Liu Y, Yang Y, Bates S, Zhang JT (2004) Characterization of oligomeric human half-ABC transporter ATP-binding cassette G2. J Biol Chem 279:19781-19789
54. Bates SE, Robey R, Miyake K, Rao K, Ross DD, Litman T (2001) The role of half-transporters in multidrug resistance. J Bioenerg Biomembr 33:503-511
55. Schellens JH, Maliepaard M, Scheper RJ, Scheffer GL, Jonker JW, Smit JW, Beijnen JH, Schinkel AH (2000) Transport of topoisomerase inhibitors by the breast cancer resistance protein. Potential clinical implications. Ann NY Acad Sci 922:188-194
56. Maliepaard M, van Gastelen MA, de Jong LA, Pluim D, van Waardenburg RC, Ruevekamp-Helmers MC, Floot BG, Schellens JH (1999) Overexpression of the BCRP/MXR/ABCP gene in a topotecan selected ovarian tumor cell line. Cancer Res 59:4559-4563
57. Litman T, Brangi M, Hudson E, Fetsch P, Abati A, Ross DD, Miake K, Resau JH, Bates S (2000) The multidrug resistant phenotype associated with overexpression of a new ABC half-transporter, MXR (ABCG2). J Cell Sci 113:2011-2021
58. Robey RW, Medina-Perez WY, Nishiyama K, Lahusen T, Miyake K, Litman T, Senderowicz AM, Ross DD, Bates SE (2001) Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCPI), in flavopiridol-resistant human breast cancer cells. Clin Cancer Res 7:145-152
59. Ozvegy-Laczka C, Hegedus T, Varady G, Ujhelly O, Schuetz JD, Varadi A, Keri G, Orfi L, Nemet K, Sarkadi B (2004) High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol Pharmacol 65:1485-1495
60. Burger H, Van Tol H, Boersma AW, Brok M, Wiemer EA, Stoter G, Nooter K (2004) Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood 104:2940-2942
61. Scharenberg CW, Harkey MA, Torok-Storb B (2002) The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood 99:507-512
62. Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ, Lagutina I, Grosveld GC, Osawa M, Nakauchi H, Sorrentino BP (2001) The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side population phenotype. Nat Med 7:1028-1034
63. Schinkel AH (2003) Mammalian ABC transporters involved in drug resistance, pharmacokinetics and detoxification. ABC2003 FEBS Advanced Lecture Course (2003), p 60
64. Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH, van de Vijver MJ, Scheper RJ, Schellens JH (2001) Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 61:3458-3464
65. Plasschaert SL, van der Kolk DM, de Bont ES, Kamps WA, Morisaki K, Bates SE, Scheffer GL, Scheper RJ, Vellenga E, de Vries EG (2003) The role of breast cancer resistance protein in acute lymphoblastic leukemia. Clin Cancer Res 9:5171-5177
66. Ross DD, Karp JE, Chen TT, Doyle LA (2000) Expression of breast cancer resistance protein in blast cells from patients with acute leukemia. Blood 96:365-368
67. Sauerbrey A, Sell W, Steinbach D, Voigt A, Zintl F (2002) Expression of the BCRP gene (ABCG2/MXR/ABCP) in childhood acute lymphoblastic leukaemia. Br J Haematol 118:147-150
68. Van den Heuvel-Eibrink MM, Wiemer EA, Prins A, Meijerink JP, Vossebeld PJ, Van den Holt B, Pieters R, Sonneveld P (2002) Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory myeloid leukemia (AML). Leukemia 16:833-839
69. Honjo Y, Hrycyna CA, Yan QW, Medina-Perez WY, Robey RW, van de Laar A, Litman T, Dean M, Bates SE (2001) Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Res 61:6635-6659
70. Allen JD, Jackson SC, Schinkel AH (2002) A mutation hot spot in the Bcrpl (Abcg2) multidrug transporter in mouse cell lines selected for Doxorubicin resistance. Cancer Res 62:2294-2299
71. Volk EL, Farley KM, Wu Y, Li F, Robey RW, Schneider E (2002) Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance. Cancer Res 62:5035-5040
72. Chen ZS, Robey RW, Belinsky MG, Shchaveleva I, Ren XQ, Sugimoto Y, Ross DD, Bates SE, Kruh GD (2003) Transport of methotrexate, methotrexate poly glutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer Res 63:4048-4054
73. Bertino JR (1993) Ode to methotrexate. J Clin Oncol 11:5-14
74. Peters GJ, Schornagel JH, Milano GA (1993) Clinical pharmacokinetics of anti-metabolites. Cancer Surv 17:123-156
75. Purcell WT, Ettinger DS (2003) Novel antifolate drugs. Curr Oncol Rep 5:114-125
76. Hooijberg JH, Broxterman HJ, Kool M, Assaraf YG, Peters GJ, Noordhuis P, Scheper RJ, Borst P, Pinedo HM, Jansen G (1999) Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res 59:2532-2535
77. Sirotnak FM, Wendel HG, Bornmann WGB, Tong WP, Miller VA, Scher HI, Kris MG (2000) Co-administration of probenecid, an inhibitor of a cMOAT/MRP-like plasma membrane ATPase, greatly enhanced the efficacy of a new 10-deazaaminopterin against human solid tumors in vivo. Clin Cancer Res 6:3705-3712
78. Kusuhara H, Suzuki H, Naito M, Tsuruo T, Sugiyama Y (1998) Characterization of efflux transport of organic anions in a mouse brain capillary endothelial cell line. J Pharmacol Exp Ther 285:1260-1265
79. Kool M, van der Linden M, de Haas M, Scheffer GL, de Vree JM, Smith AJ, Jansen G, Peters GJ, Ponne N, Scheper RJ, Elferink RP, Baas F, Borst P (1999) MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc Natl Acad Sci USA 96:6914-6919
80. Chen ZS, Lee K, Walther S, Raftogianis RB, Kuwano M, Zeng H, Kruh GD (2002) Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res 62:3144-3150
81. Zeng H, Chen ZS, Belinsky MG, Rea PA, Kruh GD (2001) Transport of methotrexate (MTX) and folates by the multidrug resistance protein (MRP3 and MRP 1) effect of polyglutamylation on MTX transport. Cancer Res 61:7225-7232
82. Heijn M, Hooijberg JH, Scheffer GL, Szabo G, Westerhoff HV, Lankelma J (1997) Anthracyclines modulate multidrug resistance protein (MRP) mediated organic anion transport. Biochim Biophys Acta 1326:12-22
83. Ito K, Oleschuk CJ, Westlake C, Vasa MZ, Deeley RG, Cole SP (2001) Mutation of Trp1254 in the multispecific organic anion transporter, multidrug resistance protein 2 (MRP2) (ABCC2), alters substrate specificity and results in loss of methotrexate transport activity. J Biol Chem 276:38108-38114
84. Lee K, Klein-Szanto AJ, Kruh GD (2000) Analysis of the MRP4 drug resistance profile in transfected NIH3T3 cells. J Natl Cancer Inst 92:1934-1940
85. Volk EL, Rohde K, Rhee M, McGuire JJ, Doyle LA, Ross DD, Schneider E (2000) Methotrexate cross-resistance in a mitoxantrone selected multidrug-resistant MCF7 breast cancer cell line is attributable to enhanced energy-dependent drug efflux. Cancer Res 60:3514-3521
86. Shafran A, Ifergan I, Bram E, Jansen G, Kathmann I, Peters GJ, Robey RW, Bates SE, Assaraf YG (2005) ABCG2 harboring the Gly482 mutation confers high-level resistance to various hydrophilic antifolates. Cancer Res 65:8414-8422
87. Sirotnak FM (1985) Obligate genetic expression in tumor cells of a fetal membrane property mediating "folate" transport: biological significance and implications for improved therapy of human cancer. Cancer Res 45:3992-4000
88. Sirotnak FM, Tolner B (1999) Carrier-mediated membrane transport of folates in mammalian cells. Annu Rev Nutr 19:91-122
89. Sierra EE, Goldman ID (1999) Recent advances in the understanding of the mechanism of membrane transport of folates and antifolates. Semin Oncol 26(2 Suppl 6):11-23
90. Henderson GB (1990) Folate-binding proteins. Annu Rev Nutr 10:319-335
91. Kamen B (1997) Folate and antifolate pharmacology. Semin Oncol 24(5 Suppl 18):S18-S39
92. Matherly LH, Goldman ID (2003) Membrane transport of folates. Vitam Horm 66:403-456
93. Westerhof GR, Jansen G, van Emmerik N, Kathmann I, Rijksen G, Jackman AL, Schornagel JH (1991) Membrane transport of natural folates and antifolate compounds in murine L1210 leukemia cells: role of carrier- and receptor-mediated transport systems. Cancer Res 51:5507-5513
94. Westerhof GR, Schornagel JH, Rijnboutt S, Pinedo HM, Jansen G (1993) Identification of a reduced folate/methotrexate carrier in human KB-cells expressing high levels of membrane associated folate binding protein. Adv Exp Med Biol 338:771-774
95. Westerhof GR, Rijnboutt S, Schornagel JH, Pinedo HM, Peters GJ, Jansen G (1995) Functional activity of the reduced folate carrier in KB, MA104, and IGROV-I cells expressing folate-binding protein. Cancer Res 55:3795-3802
96. McGuire JJ, Hsieh P, Coward JK, Bertino JR (1980) Enzymatic synthesis of folylpolyglutamates. Characterization of the reaction and its products. J Biol Chem 255:5776-5788
97. Zhao R, Gao F, Hanscom M, Goldman ID (2004) A prominent low-pH methotrexate transport activity in human solid tumors: contribution to the preservation of methotrexate pharmacologic activity in HeLa cells lacking the reduced folate carrier. Clin Cancer Res 10:718-727
98. McGuire JJ, Bertino JR (1981) Enzymatic synthesis and function of folylpolyglutamates. Mol Cell Biochem 38:19-48
99. Cook JD, Cichowicz DJ, George S, Lawler A, Shane B (1987) Mammalian folylpoly-gamma-glutamate synthetase. 4. In vitro and in vivo metabolism of folates and analogues and regulation of folate homeostasis. Biochemistry 26:530-539
100. Lowe KE, Osborne CB, Lin BF, Kim JS, Hsu JC, Shane B (1993) Regulation of folate and one-carbon metabolism in mammalian cells. II. Effect of folylpoly-gamma-glutamate synthetase substrate specificity and level on folate metabolism and folylpoly-gamma-glutamate specificity of metabolic cycles of one-carbon metabolism. J Biol Chem 268:21665-21673
101. Osborne CB, Lowe KE, Shane B (1993) Regulation of folate and one-carbon metabolism in mammalian cells. I. Folate metabolism in Chinese hamster ovary cells expressing Escherichia coli or human folylpoly-gamma-glutamate synthetase activity. J Biol Chem 268:21657-21664
102. Moran RG (1999) Roles of folylpoly-gamma-glutamate synthetase in therapeutics with tetrahydrofolate antimetabolites: an overview. Semin Oncol 26(2 Suppl 6):24-32
103. Scott JM (1992) Folate-vitamin B12 interrelationships in the nervous system. Proc Nutr Soc 51:219-224
104. Jhaveri MS, Wagner C, Trepel JB (2001) Impact of extrecellular folate levels on global gene expression. Mol Pharmacol 60:1288-1295
105. Zingg JM, Jones PA (1997) Genetic and epigenetic aspects of DNA methylation on genome expression, evolution, mutation and carcinogenesis. Carcinogenesis 18:869-882
106. Wills L (1931) Treatment of 'pernicious anaemia of pregnancy' and 'tropical anaemia' with special reference to yeast extract as curative agent. Br Med J I:1059-1064
107. Chanarin I (1979) In: Megaloblastic anaemias, 2nd edn. Blackwell, Oxford
108. Scott JM, Weir DG (1994) Folate/Vitamin B 12 interrelationships. Essays Biochem 28:63-72
109. Stanger O (2002) Physiology of folic acid in health and disease. Curr Drug Metab 3:211-223
110. Rampersaud GC, Kauwell GP, Bailey LB (2003) Folate: a key to optimizing health and reducing disease risk in the elderly. J Am Coll Nutr 22:1-8
111. Haynes WG (2002) Hyperhomocysteinemia, vascular function and atherosclerosis: effects of vitamins. Cardiovasc Drugs Ther 16:391-399
112. Kim YI (2003) Role of folate in colon cancer development and progression. J Nutr 133(11 Suppl 1):3731S-3739S
113. Choi SW, Mason JB (2000) Folate and carcinogenesis: an integrated scheme. J Nutr 130:129-132
114. Choi SW, Mason JB (2002) Folate status: effects on pathways of colorectal carcinogenesis. J Nutr 132(8 Suppl):2413S-2418S
115. Prinz-Langenohl R, Fohr I, Pietrzik K (2001) Beneficial role for folate in the prevention of colorectal and breast cancer. Eur J Nutr 40:98-105
116. Mason JB (2002) Nutritional chemoprevention of colon cancer. Semin Gastrointest Dis 13:143-153
117. Selhub J (2002) Folate, vitamin B 12 and vitamin B6 and one carbon metabolism. J Nutr Health Aging 6:39-42
118. De Bree A, van Dusseldorp M, Brouwer IA, van het Hof KH, Steegers-Theunissen RP (1997) Folate intake in Europe: recommended, actual and desired intake. Eur J Clin Nutr 51:643-660
119. Ladas EJ, Jacobson JS, Kennedy DD, Teel K, Fleischauer A, Kelly KM (2004) Antioxidants and cancer therapy: a systematic review. J Clin Oncol 22:517-528
120. Rots MG, Pieters R, Peters GJ, Noordhuis P, Van Zantwijk CH, Kaspers GJL, Hahlen K, Creutzig U, Veerman AJP, Jansen G (1999) Role of folylpolyglutamate synthetase and folylpolyglutarnate hydrolase in methotrexate accumulation and polyglutarnylation in childhood leukemia. Blood 93:1677-1683
121. McGuire JJ (2003) Anticancer antifolates: current status and future directions. Curr Pharm Des 9:2593-2613
122. Zhao R, Goldman ID (2003) Resistance to antifolates. Oncogene 22:7431-7457
123. Schimke RT (1986) Methotrexate resistance and gene amplification. Mechanisms and implications. Cancer Res 56:1912-1917
124. Li WW, Lin JT, Tong WP, Trippett TM, Brennan MF, Bertino JR (1992) Mechanisms of natural resistance to antifolates in human soft tissue sarcomas. Cancer Res 52:1434-1438
125. McCloskey DE, McGuire JJ, Russell CA, Rowan BG, Bertino JR, Pizzorno G, Mini E (1991) Decreased folylpolyglutamate synthetase activity as a mechanism of methotrexate resistance in CCRF-CEM human leukemia sublines. J Biol Chem 266:6181-6187
126. Matherly LH, Taub JW, Ravindranath Y, Proefke SA, Wong SC, Gimotty P, Buck S, Wright JE, Rosowsky A (1995) Elevated dihydrofolate reductase and impaired methotrexate transport as elements in methotrexate resistance in childhood acute lymphoblastic leukemia. Blood 85:500-509
127. Hill BT, Bailey BD, White JC, Goldman ID (1979) Characteristics of transport of 4-amino antifolates and folate compounds by two lines of L5178Y lymphoblasts, one with impaired transport of methotrexate. Cancer Res 39:2440-2446
128. Gorlick R, Goker E, Trippett T, Waltham M, Banerjee D, Bertino JR (1996) Intrinsic and acquired resistance to methotrexate in acute leukemia. N Engl J Med 335:1041-1048
129. Jansen G, Mauritz R, Drori S, Sprecher H, Kathmann I, Bunni MA, Priest DG, Noordhuis P, Schornagel JH, Pinedo HM, Peters GJ, Assaraf YG (1998) Structurally altered human reduced folate carrier with increased folic acid transport mediates a novel mechanism of antifolate resistance. J Biol Chem 273:30189-30198
130. Jansen G, Barr HM, Kathmann I, Bunni MA, Priest DG, Noordhuis P, Peters GJ, Assaraf YG (1999) Multiple mechanisms of resistance to polyglutamatable and lipophilic antifolates in mammalian cells: role of increased folylpolyglutamylation, expanded folate pools, and intralysosomal drug sequestration. Mol Pharmacol 55:761-769
131. Tse A, Moran RG (1998) Cellular folates prevent polyglutamylation of 5,10-dideaza-tetrahydrofolate. J Biol Chem 273:25944-25952
132. Faessel HM, Slocum HK, Jackson RC, Boritzski TJ, Rustum YM, Nair MG, Greco WR (1998) Super in vitro synergy between inhibitors of dihydrofolate reductase and inhibitors of other folate-requiring requiring enzymes: the critical role of polyglutamylation. Cancer Res 58:3036-3050
133. Assaraf YG, Goldman ID (1997) Loss of folic acid exporter function with markedly augmented folate accumulation in lipophilic antifolate-resistant mammalian cells. J Biol Chem 272:17460-17466
134. Alati T, Worzalla JF, Shih C, Bewley JR, Lewis S, Moran RG, Grindey GB (1996) Augmentation of the therapeutic activity of lometrexol-(6-R)5,10-dideazatetreahydrofolate by oral folic acid. Cancer Res 15:2331-2335
135. Smith GK, Amyx H, Boytos CM, Duch DS, Ferone R, Wilson HR (1995) Enhanced antitumor activity for the thymidylate synthase inhibitor 1843U89 through decreased host toxicity with oral folic acid. Cancer Res 55:6117-6125
136. Schmitz JC, Grindey GB, Schultz RM, Priest DG (1994) Impact of dietary folic acid on reduced folates in mouse plasma and tissues. Relationships to di deazatetra hydrofolate sensitivity. Biochem Pharmacol 48:319-325
137. Kusuhara H, Han Yhm Shimoda M, Kokue E, Suzuki H, Sugiyama Y (1998) Reduced folate derivatives are endogenous substrates for cMOAT in rats. Am J Physiol 275:G789-G796
138. Van der Wilt CL, Backus HH, Smid K, Comijn L, Veerman G, Wouters D, Voorn DA, Priest DG, Bunni MA, Mitchell F, Jackman AL, Jansen G, Peters GJ (2001) Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors. Cancer Res 61:3675-3681
139. Zervos PH, Allen RH, Thornton DE, Thiem PA (1997) Functional folate status as a prognostic indicator of toxicity in clinical trials of the multitargeted antifolate LY231514. Eur J Cancer (suppl)33:S18
140. Niyikiza C, Hanauske AR, Rusthoven JJ, Calvert AH, Allen R, Paoletti P, Bunn PA Jr (2002) Pemetrexed safety and dosing strategy. Sem Oncol 6(Suppl 18) 24-29
141. Peters GJ, Jansen G (2001) Folate homeostasis and antiproliferative activity of folates and antifolates. Nutrition 17:737-738
142. Bertino JR (1977) "Rescue" techniques in cancer chemotherapy: use of leucovorin and other rescue agents after methotrexate treatment. Semin Oncol 4:203-216
143. Calvert H (2003) Pemetrexed (Alimta): a promising new agent for the treatment of breast cancer. Semin Oncol 30(2 Suppl 3):2-5
144. Vogelzang NJ, Rusthoven J, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural meso-thelioma. J Clin Oncol 21:2636-2644
145. Stark M, Rothem L, Jansen G, Scheffer GL, Goldman ID, Assaraf YG (2003) Antifolate resistance associated with loss of MRP1 expression and function in Chinese hamster ovary cells with markedly impaired export of folate and cholate. Mol Pharmacol 64:220-227
146. Hooijberg JH, Peters GJ, Assaraf YG, Kathmann I, Priest DG, Bunni MA, Veerman AJ, Scheffer GL, Kaspers GJ, Jansen G (2003) The role of multidrug resistance proteins MRP1, MRP2 and MRP3 in cellular folate homeostasis. Biochem Pharmacol 65:765-771
147. Ifergan I, Shafran A, Jansen G, Hooijberg JH, Scheffer GL, Assaraf YG (2004) Folate deprivation results in the loss of breast cancer resistance protein (BCRP/ABCG2) expression. A role for BCRP in cellular folate homeostasis. J Biol Chem 279:25527-25534
148. Assaraf YG, Rothem L, Hooijberg JH, Stark M, Ifergan I, Kathmann I, Dijkmans BA, Peters GJ, Jansen G (2003) Loss of multidrug resistance protein 1 expression and folate efflux activity results in a highly concentrative folate transport in human leukemia cells. J Biol Chem 278:6680-6686
149. Hooijberg JH, Jansen G, Assaraf YG, Kathmann I, Pieters R, Laan AC, Veerman AJP, Kaspers GJ, Peters GJ (2004) Folate concentration dependent transport activity of the Multidrug Resistance Protein 1 (ABCC1). Biochem Pharmacol 67:1541-1548